JP6442475B2 - Ｌｘｒ調節因子 - Google Patents
Ｌｘｒ調節因子 Download PDFInfo
- Publication number
- JP6442475B2 JP6442475B2 JP2016502750A JP2016502750A JP6442475B2 JP 6442475 B2 JP6442475 B2 JP 6442475B2 JP 2016502750 A JP2016502750 A JP 2016502750A JP 2016502750 A JP2016502750 A JP 2016502750A JP 6442475 B2 JP6442475 B2 JP 6442475B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- mmol
- compound
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Br*1CCCCCCC1 Chemical compound Br*1CCCCCCC1 0.000 description 5
- PXLGKFGVXLWXFV-UHFFFAOYSA-N CCOC(c(nc1C)c[n]1-c(c(-c1c(-c(cc2)cc(O3)c2OC3(F)F)[o]c(C)n1)c1)ccc1Br)=O Chemical compound CCOC(c(nc1C)c[n]1-c(c(-c1c(-c(cc2)cc(O3)c2OC3(F)F)[o]c(C)n1)c1)ccc1Br)=O PXLGKFGVXLWXFV-UHFFFAOYSA-N 0.000 description 2
- XJGLXJFLLIBLFQ-UHFFFAOYSA-N Cc1nc(C(O)=O)c[n]1-c(ccc(Br)c1)c1-c1c(-c(cc2)cc(O3)c2OC3(F)F)[o]c(C)n1 Chemical compound Cc1nc(C(O)=O)c[n]1-c(ccc(Br)c1)c1-c1c(-c(cc2)cc(O3)c2OC3(F)F)[o]c(C)n1 XJGLXJFLLIBLFQ-UHFFFAOYSA-N 0.000 description 2
- OYNZRUMZLYTPGO-RWANSRKNSA-N C=CC[C@H](C(C1)N=NN1c(cc(cc1Cl)[N+]([O-])=O)c1-[n]1cnc(C(F)(F)F)c1)Cl Chemical compound C=CC[C@H](C(C1)N=NN1c(cc(cc1Cl)[N+]([O-])=O)c1-[n]1cnc(C(F)(F)F)c1)Cl OYNZRUMZLYTPGO-RWANSRKNSA-N 0.000 description 1
- HOZREFFNUJAHQP-UHFFFAOYSA-N CC(C(c(cc1)ccc1Cl)=O)=O Chemical compound CC(C(c(cc1)ccc1Cl)=O)=O HOZREFFNUJAHQP-UHFFFAOYSA-N 0.000 description 1
- GUISAQUVDRQYNT-UHFFFAOYSA-N CC(c(nc1C)c[n]1-c(ccc(-c1cc(S(C)(=O)=O)ccc1)c1)c1-c1c(-c(cc2)cc(O3)c2OC3(F)F)[o]c(C)n1)O Chemical compound CC(c(nc1C)c[n]1-c(ccc(-c1cc(S(C)(=O)=O)ccc1)c1)c1-c1c(-c(cc2)cc(O3)c2OC3(F)F)[o]c(C)n1)O GUISAQUVDRQYNT-UHFFFAOYSA-N 0.000 description 1
- CHLGBYJEMLCJJJ-UHFFFAOYSA-N CC1(C)OB(c2cccc(C(N(C)C)=O)c2)OC1(C)C Chemical compound CC1(C)OB(c2cccc(C(N(C)C)=O)c2)OC1(C)C CHLGBYJEMLCJJJ-UHFFFAOYSA-N 0.000 description 1
- YAWKCVLYCIAEJA-UHFFFAOYSA-N COC(c(cc1)cc(C2=O)c1OC2F)=O Chemical compound COC(c(cc1)cc(C2=O)c1OC2F)=O YAWKCVLYCIAEJA-UHFFFAOYSA-N 0.000 description 1
- CXPJHVIGQJKJJY-UHFFFAOYSA-N COC(c(cc12)ccc1OCC2=O)=O Chemical compound COC(c(cc12)ccc1OCC2=O)=O CXPJHVIGQJKJJY-UHFFFAOYSA-N 0.000 description 1
- BVVKCOTWBDPDFW-UHFFFAOYSA-N CS(c1cccc(-c(cc2Cl)cc(-[n]3nncc3-c(cc3)ccc3Cl)c2-[n]2cnc(C(F)(F)F)c2)c1)(=O)=O Chemical compound CS(c1cccc(-c(cc2Cl)cc(-[n]3nncc3-c(cc3)ccc3Cl)c2-[n]2cnc(C(F)(F)F)c2)c1)(=O)=O BVVKCOTWBDPDFW-UHFFFAOYSA-N 0.000 description 1
- FCPJEFWGPFBIMY-UHFFFAOYSA-N Cc1nc(C(F)(F)F)c[n]1-c(c(-[n]1nncc1C(c(cc1)ccc1Cl)(F)F)c1)ccc1-c1cccc(S(C)(=O)=O)c1 Chemical compound Cc1nc(C(F)(F)F)c[n]1-c(c(-[n]1nncc1C(c(cc1)ccc1Cl)(F)F)c1)ccc1-c1cccc(S(C)(=O)=O)c1 FCPJEFWGPFBIMY-UHFFFAOYSA-N 0.000 description 1
- RRTBSPZBXPIXCD-UHFFFAOYSA-N Cc1nc(C(F)(F)F)c[n]1-c(c(-c1c(-c(cc2)ccc2Cl)nc[o]1)c1)ccc1-c1cc(F)c(CO)c(S(C)(=O)=O)c1 Chemical compound Cc1nc(C(F)(F)F)c[n]1-c(c(-c1c(-c(cc2)ccc2Cl)nc[o]1)c1)ccc1-c1cc(F)c(CO)c(S(C)(=O)=O)c1 RRTBSPZBXPIXCD-UHFFFAOYSA-N 0.000 description 1
- DSKGTZYUKPWROY-UHFFFAOYSA-N Cc1nc(C(F)(F)F)c[n]1-c(ccc(-c1cc(S(C)(=O)=O)ccc1)c1)c1-c1c(-c(cc2)ccc2Cl)[o]cn1 Chemical compound Cc1nc(C(F)(F)F)c[n]1-c(ccc(-c1cc(S(C)(=O)=O)ccc1)c1)c1-c1c(-c(cc2)ccc2Cl)[o]cn1 DSKGTZYUKPWROY-UHFFFAOYSA-N 0.000 description 1
- RTULQGBLFFZOCE-UHFFFAOYSA-N Cc1nc(C(F)(F)F)c[n]1-c(ccc(-c1cc(S(C)(=O)=O)ccc1)c1)c1-c1c(-c(cc2C3O)ccc2OC3(F)F)[o]c(C)n1 Chemical compound Cc1nc(C(F)(F)F)c[n]1-c(ccc(-c1cc(S(C)(=O)=O)ccc1)c1)c1-c1c(-c(cc2C3O)ccc2OC3(F)F)[o]c(C)n1 RTULQGBLFFZOCE-UHFFFAOYSA-N 0.000 description 1
- LALSMKYTJGUXAO-UHFFFAOYSA-N Cc1nc(C(N)=O)c[n]1-c(c(-c1c(-c(cc2)cc(O3)c2OC3(F)F)[o]c(C)n1)c1)ccc1Br Chemical compound Cc1nc(C(N)=O)c[n]1-c(c(-c1c(-c(cc2)cc(O3)c2OC3(F)F)[o]c(C)n1)c1)ccc1Br LALSMKYTJGUXAO-UHFFFAOYSA-N 0.000 description 1
- ZVYCNOLMFVSXOK-UHFFFAOYSA-N Cc1nc(CO)c[n]1-c(ccc(Br)c1)c1-c1c(-c(cc2)cc(O3)c2OC3(F)F)[o]c(C)n1 Chemical compound Cc1nc(CO)c[n]1-c(ccc(Br)c1)c1-c1c(-c(cc2)cc(O3)c2OC3(F)F)[o]c(C)n1 ZVYCNOLMFVSXOK-UHFFFAOYSA-N 0.000 description 1
- DBIGDAIVQGYSSM-UHFFFAOYSA-N O=C(C=P(c1ccccc1)(c1ccccc1)c1ccccc1)c(cc1)ccc1Cl Chemical compound O=C(C=P(c1ccccc1)(c1ccccc1)c1ccccc1)c(cc1)ccc1Cl DBIGDAIVQGYSSM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786974P | 2013-03-15 | 2013-03-15 | |
| US61/786,974 | 2013-03-15 | ||
| PCT/US2014/028274 WO2014144037A1 (en) | 2013-03-15 | 2014-03-14 | Lxr modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513730A JP2016513730A (ja) | 2016-05-16 |
| JP2016513730A5 JP2016513730A5 (enExample) | 2017-04-20 |
| JP6442475B2 true JP6442475B2 (ja) | 2018-12-19 |
Family
ID=51537598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502750A Expired - Fee Related JP6442475B2 (ja) | 2013-03-15 | 2014-03-14 | Ｌｘｒ調節因子 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9834542B2 (enExample) |
| EP (1) | EP2968275B1 (enExample) |
| JP (1) | JP6442475B2 (enExample) |
| CN (1) | CN105209039B (enExample) |
| WO (1) | WO2014144037A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2694001T3 (es) | 2013-03-15 | 2018-12-17 | Bristol-Myers Squibb Company | Moduladores de LXR |
| WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
| CN104817525B (zh) * | 2015-04-13 | 2017-11-17 | 江苏大学 | 含氟2,3‑二氢苯并呋喃‑3‑醇类化合物及制备方法 |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| CN109867645B (zh) * | 2017-12-05 | 2021-09-14 | 中国医学科学院药物研究所 | 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法 |
| TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
| EP3927693A4 (en) * | 2019-02-21 | 2023-04-05 | Nanjing Ruijie Pharma Co., Ltd. | NOVEL COMPOUNDS AND THEIR USES AS THYROID HORMONE RECEPTOR AGONISTS |
| CN110330493B (zh) * | 2019-08-23 | 2020-07-24 | 广州麓鹏制药有限公司 | Pim激酶抑制剂、其制备方法、应用、药物及药物组合 |
| WO2021119397A1 (en) | 2019-12-13 | 2021-06-17 | Rgenix, Inc. | Metal salts and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| WO1984002131A1 (fr) | 1982-11-22 | 1984-06-07 | Sandoz Ag | Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| EP0252290B1 (en) | 1986-06-10 | 1992-06-03 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof |
| US5138069A (en) | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| AU714851B2 (en) | 1996-04-03 | 2000-01-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5874452A (en) | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| AU716381B2 (en) | 1996-04-03 | 2000-02-24 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5859035A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| US5854265A (en) | 1996-04-03 | 1998-12-29 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| PL334840A1 (en) | 1997-01-24 | 2000-03-27 | Univ California | Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation |
| EP1059843A1 (en) | 1998-02-25 | 2000-12-20 | Merck & Co., Inc. | Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist |
| AU5994199A (en) | 1998-09-23 | 2000-04-10 | Alexander Mata De Urquiza | Analysis of ligand activated nuclear receptors (in vivo) |
| EP1140079B1 (en) | 1998-12-23 | 2009-06-03 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| WO2000078972A2 (en) | 1999-06-18 | 2000-12-28 | Cv Therapeutics, Inc. | Regulation with binding cassette transporter protein abc1 |
| WO2001082917A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
| MX2008000141A (es) | 2005-06-27 | 2008-04-07 | Exelixis Inc | Moduladores de lxr basados en imidazol. |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| EP2121621B1 (en) * | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
| DK2435410T3 (da) * | 2009-05-28 | 2017-04-10 | Exelixis Patent Co Llc | LXR-modulatorer |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| ES2694001T3 (es) | 2013-03-15 | 2018-12-17 | Bristol-Myers Squibb Company | Moduladores de LXR |
-
2014
- 2014-03-14 WO PCT/US2014/028274 patent/WO2014144037A1/en not_active Ceased
- 2014-03-14 EP EP14763091.7A patent/EP2968275B1/en not_active Not-in-force
- 2014-03-14 US US14/774,844 patent/US9834542B2/en active Active
- 2014-03-14 JP JP2016502750A patent/JP6442475B2/ja not_active Expired - Fee Related
- 2014-03-14 CN CN201480027783.0A patent/CN105209039B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2968275B1 (en) | 2017-11-29 |
| WO2014144037A1 (en) | 2014-09-18 |
| EP2968275A4 (en) | 2016-08-10 |
| CN105209039B (zh) | 2018-06-22 |
| CN105209039A (zh) | 2015-12-30 |
| US9834542B2 (en) | 2017-12-05 |
| JP2016513730A (ja) | 2016-05-16 |
| US20160304499A1 (en) | 2016-10-20 |
| EP2968275A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6442475B2 (ja) | Ｌｘｒ調節因子 | |
| CN101679297B (zh) | Lxr和fxr调节剂 | |
| JP5244589B2 (ja) | イミダゾールに基づくｌｘｒモジュレーター | |
| RU2681537C2 (ru) | Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение | |
| JP5625050B2 (ja) | Ｌｘｒの調節因子 | |
| JP6456909B2 (ja) | Ｌｘｒ調節因子 | |
| CZ243093A3 (en) | Benzofuran derivatives, process of their preparation and pharmaceutical preparations in which they are comprised | |
| KR102000319B1 (ko) | Trpm8 길항제 | |
| WO2003103654A1 (ja) | ＮＦ−κＢ活性化阻害剤 | |
| WO1998046594A1 (en) | Pyrazole derivatives and cox inhibitors containing them | |
| EA022799B1 (ru) | Пиразолилзамещенные производные угольной кислоты в качестве модуляторов рецептора простациклина (pgi2), применимые для лечения связанных с ним нарушений | |
| JP2019528262A (ja) | Ｇｐｒ４０−アゴニストおよびｇｐｒ１２０−アゴニストとしてのスルホンアミド類 | |
| KR101685993B1 (ko) | 전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물 | |
| WO2004031180A1 (ja) | キナゾリン−４−オン誘導体 | |
| KR20160048996A (ko) | 간 x 수용체 (lxr) 조절인자 | |
| KR20050073110A (ko) | 간 ｘ 수용체의 항진제 | |
| SI9200253A (sl) | Derivati benzofurana |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170313 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170313 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180220 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180518 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180720 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181030 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181126 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6442475 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |